ArticlePLoS neglected tropical diseases2026
Development and international multicenter evaluation of a second-generation immunochromatography test for the serological diagnosis of melioidosis.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Melioidosis is a life-threatening infectious disease caused by Burkholderia pseudomallei. Early and accurate diagnosis is critical for timely treatment and improved outcomes. Although highly endemic in tropical regions, it remains underdiagnosed due to limitations of current diagnostic methods. Bacterial culture, the diagnostic gold standard, is time-consuming, prone to misidentified species, requires specialized laboratory facilities, and has low sensitivity. The indirect hemagglutination assay is also unreliable due to poor sensitivity and specificity. We developed a second-generation immunochromatography test (Hcp1-ICT) to detect anti-Hcp1 IgG antibodies against hemolysin co-regulated protein 1 of B. pseudomallei and evaluated its diagnostic performance in an international multi-center study. A total of 1,838 stored serum samples from 601 culture-proven melioidosis patients, 598 healthy individuals and 639 patients with non-melioidosis infections in Thailand, Lao PDR, Vietnam, Malaysia, Sri Lanka, Cambodia, and Australia were analyzed for diagnosis of melioidosis. The sensitivities in Thailand, Lao PDR, Vietnam, Malaysia, Sri Lanka, Cambodia, and Australia were 92%, 77%, 76%, 80%, 74%, 90%, and 48%, respectively. The specificities with healthy donor samples were 96%, 79%, 98%, 100%, 100%, 87%, and 100%, while the specificities for cases with samples from other infections other than melioidosis were 97%, 87%, 98%, 98%, 100%, 90%, and 94%, respectively. These findings indicate that the Hcp1-ICT is a promising point-of-care tool for serodiagnosis of melioidosis. However, its variable performance across regions underscores the need for prospective validation locally in various regions to optimize its diagnostic utility and facilitate implementation in both referral centers and resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.